TY  - GEN
AU  - Burki,Talha Khan
TI  - Preliminary activity of capmatinib with gefitinib in NSCLC
SN  - 1474-5488
PY  - 2019///0617
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Benzamides
KW  - Biomarkers, Tumor
KW  - antagonists & inhibitors
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Clinical Trials, Phase I as Topic
KW  - Clinical Trials, Phase II as Topic
KW  - ErbB Receptors
KW  - Gefitinib
KW  - administration & dosage
KW  - Genetic Predisposition to Disease
KW  - Humans
KW  - Imidazoles
KW  - Lung Neoplasms
KW  - Maximum Tolerated Dose
KW  - Mutation
KW  - Phenotype
KW  - Protein Kinase Inhibitors
KW  - Time Factors
KW  - Treatment Outcome
KW  - Triazines
N1  - Publication Type: News
UR  - https://doi.org/10.1016/S1470-2045(18)30678-8
ER  -